One of the few bright spots on the OTC Markets today came from the everlasting run the penny stock of ScripsAmerica, Inc. (SCRC) has been on. Setting a new 52 week high at 0.54 on Tuesday, SCRC stock has offered traders gains of over 386% in the last 2 months. With expansion plans in the works for their signature drug RapiMed®, a children’s pain reliever which is succeeding because of its speed, effectiveness, dosing accuracy and safety, it’s a relief to know not all of the OTC stocks are crumbling.
Our Next Pick Is Coming Soon! Click HERE To Make Sure You Don’t Miss Any Of Our Breaking Alerts!
SCRC Stock Quote
Market Cap: 32.46M
Last: 0.525 ▲ +0.043 (+8.92%)
Dollar Volume: $286,640
Issued and Outstanding: 61,836,821
14-Day Rel Strength: 79.42%
14-Day Stochastic: 96.15%
Looking for Hot Penny Stocks?
Click here To Receive FREE Penny Stock Alerts
ScripsAmerica issued news last week DPG Distribution was granted the exclusive right to purchase, promote and resell the Company’s RapiMed OTC products throughout North America, commencing with its children’s pain reliever and fever reducer. The deal is for 2 years if designated sales quotas are met and calls for the product to possibly be put on the shelves in places like Wal-Mart, Costco, Target, Walgreens, CVS and ShopRite.
Just 2 days prior to that announcement, ScripsAmerica also reported the intention to expand sales and distribution of its products into Asia through the Company’s financing partner in Shenzhen, China, Forbes Investments Ltd. The increase in sales would be a blessing for the Company considering that Q1 revenues of $287,374 was not able to produce a positive gross profit on operations: ($10,666).
Despite the lack of seeing big numbers on the reported revenues, there is a much larger factor which has helped SCRC stock achieve its recent gains.
In September 2012, the Company announced that their Contract Packager secured an 8-year, $79 million pharmaceutical distribution contract with the Office of Health Affairs, a branch of the U.S. Department of Homeland Security, in conjunction with the Defense Logistics Agency (DLA). On September 30, 2012, ScripsAmerica’s Contract Packager began shipping its first order on this distribution contract with the DLA.
The DLA contract with our Contract Packager calls for a minimum purchase amount of $25 million over the next 2-3 years and was awarded to the Company’s Contract Packager based on the Contract Packager’s ability to provide specified pharmaceuticals at competitive prices.
During the course of Q1, 2013, sales from DLA contract were valued at $1,955,345. The cost of those sales came in at $1,818,471 which netted the Company revenues from the Contract Packager of $136,874.
So, the plans ScripsAmerica has for expanding its products into other markets, as indicated in their recently issued PRs is not a pipe dream for the Company. Entering into China may be much more difficult than landing a U.S. government connected contract, but as long as sales continue to expand in any direction, SCRC stock could avoid returning to the 0.111 range.
About SCRC Stock
ScripsAmerica, Inc. is a healthcare services company focused on efficient supply chain management, from strategic sourcing to delivering niche generic pharmaceuticals to market.
Click here to view the SEC filings for SCRC.
Click here to view the website for ScripsAmerica.
Last 5 Trading Sessions:
Stay Connected With Us:
With all the recent awareness groups getting their penny stocks slaughtered by the pig sellers who are hiring them, finding half-decent trading opportunities like SCRC are where most are going to see the best results this summer. SCRC stock was once a profiled pick of a number of groups in recent months which only goes to prove that patience sometimes pays off great dividends when the pick is at least of a good company with growth in its front view, not its dream catcher.
Here is your opportunity to subscribe to the Most Read Penny Stock Newsletter
If You Can’t Make Money With Us, You Shouldn’t Be Trading Penny Stocks
(We are 100% Anti-Spam and will never rent or sell your information)Share